Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The main objective is to evaluate the hepatic safety of raltegravir when compared to
efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment
in patients with HIV and hepatitis C coinfection.
Phase:
Phase 4
Details
Lead Sponsor:
University of Hawaii
Collaborators:
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam Oxford University Clinical Research Unit, Vietnam Viet Tiep General Hospital, Hai Phong, Vietnam